Ken Griffin Pharma Cyte Biotech, Inc. Transaction History
Citadel Advisors LLC
- $618 Billion
- Q3 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 10,600 shares of PMCB stock, worth $8,374. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,600Holding current value
$8,374% of portfolio
0.0%Shares
7 transactions
Others Institutions Holding PMCB
# of Institutions
28Shares Held
539KCall Options Held
10.6KPut Options Held
0-
Geode Capital Management, LLC Boston, MA127KShares$100,0160.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$72,7487.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$65,3540.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny80KShares$63,2000.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA74.9KShares$59,1860.0% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $16.4M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...